Videos

The FDA adds a NAION warning to GLP-1 drugs, plus LEMS clues, Eyedaptic's new Eva AI assistant and a retinal imaging link to AFib.

R. Ross Lakhanpal, MD, FACS, Anu Patel, MD, and Yasha S. Modi, MD, MHS, point to cell replacement in geographic atrophy, care burden, and glycemic control.

Rapid early disease control may establish the trajectory for long-term outcomes in neovascular AMD, supporting first-line use of second-generation anti-VEGF agents in patients with high-risk anatomic or functional features.

A new diagnosis of neovascular age-related macular degeneration carries consequences well beyond visual acuity, and early treatment goals must balance anatomic disease control with patient confidence and long-term adherence.

Isa S. K. Mohammed, MD, on training refractive surgeons and why lasers make global access harder than for cataract surgery.

Jayakrishna Ambati, MD, discusses phase 2 K8 results in GA, its inflammasome mechanism, and dosing designed for convenience.

Hunter Cherwek, MD, of Orbis discusses summit commitments, eye care workforce training, and AI in low-resource settings.

Uday Devgan, MD, FACS, Jordana G. Fein, MD, MS, and Carl D. Regillo, MD, FASRS, point to IOL education, emerging retina therapies, and treatment burden.

Andrew G. Lee, MD, and Drew Carey, MD, break down the visual safety of flow-diverting stents for carotid-ophthalmic aneurysms.

Isa S. K. Mohammed, MD, explains how he matches patients to PRK, LASIK, SMILE, or phakic IOLs and how prior surgery affects IOLs.

Christina Y. Weng, MD, MBA, FASRS; Michael A. Singer, MD, and Isa S. K. Mohammed, MD, point to early retinal care, corticosteroid training, and regulation and waste.

In the latest episode of The Wills Retina Report, Regillo and Ho discuss where gene therapy stands for retinal disease, from late-stage programs in neovascular age-related macular degeneration to earlier efforts in geographic atrophy and diabetic retinopathy.

IRIS Registry data showed no change in anti-VEGF frequency, vision, or retinal thickness after patients with DME began a GLP-1RA.

In the latest episode of The Retina TL;DR with Dr. Weng—Part 2 of a special two-part series—host Christina Y. Weng, MD, MBA, FASRS, sits down with two more of her former residents for candid advice on transitioning into fellowship, balancing research and family, and what excites them most about the future of retina.

Murtaza K. Adam, MD, shares pearls on haptic docking, patient selection, and preventing complications with the Yamane technique.

Andrew G. Lee, MD, and Drew Carey, MD, break down the link between optic neuritis and uveitis in central nervous system demyelinating disease.

Anat Galor, MD, MSPH, discusses subtyping dry eye, emerging diagnostic tools, and when to consider oral neuromodulation.

At AAO 2026, Anjum F. Koreishi, MD, shared how to prevent complications after cataract surgery in patients with uveitis.

David F. Chang, MD, shares how to set realistic refractive IOL expectations and streamline patient counseling.

Timothy Janetos, MD, explained when to refer uveitis to a specialist and why access to uveitis care remains limited.

Himani Goyal, MD, John J. Chen, MD, PhD, and Mark P. Breazzano, MD, FACS, point to academic compensation, optic nerve damage, and who chooses retina.

LUGANO missed its visual noninferiority endpoint for the vorolanib insert vs aflibercept in nAMD despite comparable anatomic control. Regillo attributes the gap partly to 9 outliers with vision loss unrelated to nAMD.

OT Roundup covers the optogenetics Nobel Prize, remigromig in DME with Veeral Sheth, MD, Stargardt disease and a total human eye transplant.

Vaidehi Dedania, MD, discussed surgical advances, candidates, and how far whole eye transplant is from clinical use.

Anat Galor, MD, MSPH, explains how to tell whether dry eye pain stems from the nerves or the tear film and how to target it.

Timothy M. Janetos, MD, Donald J. D’Amico, MD, and Mark J. Gallardo, MD, point to uveitis access, clinical trial rigor, and procedural pharmaceuticals.

At AAO 2026, Michael T. Yen, MD, explained how at-home subcutaneous elegrobart could ease treatment burden in thyroid eye disease.

Liza M. Cohen, MD, explains when to use CT vs MRI in thyroid eye disease and why to review images yourself.